Immunogenicity and safety of two live-attenuated tetravalent dengue vaccine formulations in healthy Australian adults☆

2005/09/24 by S KITCHENER, Scott Kitchener, M NISSEN +11 · 20 citations
Medicine · #Antibody #Dengue fever #Dengue vaccine #Dengue virus #Immunogenicity #Immunology #Medicine #Mosquito-borne diseases and control #Neutralizing antibody #Reactogenicity #Serotype #Vaccination #Viral Infections and Outbreaks Research #Viral Infections and Vectors #Virology

paper · doi:10.1016/j.vaccine.2005.09.029

openalex publication_date 2005/09/24 · openalex created_date 2025/10/10 · openalex updated_date 2026/07/25

Cited by

• An adenovirus prime/plasmid boost strategy for induction of equipotent immune responses to two dengue virus serotypes. [europepmc]
• Dengue virus type 3 vaccine candidates generated by introduction of deletions in the 3' untranslated region (3'-UTR) or by exchange of the DENV-3 3'-UTR with that of DENV-4. [europepmc]
• Targeted mutagenesis as a rational approach to dengue virus vaccine development. [europepmc]
• Phase 1 trial of the dengue virus type 4 vaccine candidate rDEN4{Delta}30-4995 in healthy adult volunteers. [europepmc]
• The development of recombinant subunit envelope-based vaccines to protect against dengue virus induced disease. [europepmc]
• Development of DENVax: a chimeric dengue-2 PDK-53-based tetravalent vaccine for protection against dengue fever. [europepmc]
• Variation in dengue virus plaque reduction neutralization testing: systematic review and pooled analysis. [europepmc]
• Vaccination of volunteers with low-dose, live-attenuated, dengue viruses leads to serotype-specific immunologic and virologic profiles. [europepmc]
• Live attenuated tetravalent dengue virus host range vaccine is immunogenic in African green monkeys following a single vaccination. [europepmc]
• Induction of neutralizing antibody response against four dengue viruses in mice by intramuscular electroporation of tetravalent DNA vaccines. [europepmc]
• Safety and immunogenicity of a recombinant live attenuated tetravalent dengue vaccine (DENVax) in flavivirus-naive healthy adults in Colombia: a randomised, placebo-controlled, phase 1 study. [europepmc]
• Recent progress in dengue vaccine development. [europepmc]
• Neutropenia as an Adverse Event following Vaccination: Results from Randomized Clinical Trials in Healthy Adults and Systematic Review. [europepmc]
• Mimicking immune signatures of flavivirus infection with targeted adjuvants improves dengue subunit vaccine immunogenicity. [europepmc]
• Anti-dengue Vaccines: From Development to Clinical Trials. [europepmc]
• Well-balanced immune response and protective efficacy induced by a single dose of live attenuated tetravalent dengue vaccine (KD-382) in monkeys. [europepmc]
• Chimeric Vaccines Based on Novel Insect-Specific Flaviviruses. [europepmc]
• Identification of stage-related and severity-related biomarkers and exploration of immune landscape for Dengue by comprehensive analyses. [europepmc]
• A novel mucosal bivalent vaccine of EV-A71/EV-D68 adjuvanted with polysaccharides from Ganoderma lucidum protects mice against EV-A71 and EV-D68 lethal challenge. [europepmc]
• Viral Vectors [europepmc]